In this study of treating cUTIs with ertapenem, we have demonstrated good clinical outcomes” Trad et al (2016).
BACKGROUND: Ertapenem is a broad-spectrum antibiotic that is increasingly being utilized. Its dosing convenience renders it suitable for outpatient therapy, and its pharmacokinetic characteristics favour its use against complicated urinary tract infections (cUTIs). Despite this, sufficient clinical data are lacking for its use against cUTIs in the outpatient setting. We assessed the microbiological and clinical cure rates associated with ertapenem treatment for cUTIs in two outpatient parenteral antimicrobial therapy (OPAT) departments.
ReTweet if useful... The use of Ertapenem to UTI in the OPAT setting http://ctt.ec/H8f20+ @ivteam #ivteam
METHODS: We undertook a prospective observational study of adult patients who received ertapenem for cUTIs between August 2010 and August 2014. Data on patient characteristics, clinical progress and microbiological results were collected and analysed.
RESULTS: Sixty-one patients were enrolled. The median age was 59 years (range 24, 83) and 61% were male. The most common diagnoses were pyelonephritis (39%) and prostatitis (15%). The most common causative organism was Escherichia coli (67%). Extended-spectrum β-lactamase (ESBL)-producing organisms were detected in 72% of infections. Microbiological cure was achieved in 67% overall, and was less likely in those with Klebsiella pneumoniae infection (OR = 0.21 [95%CI: 0.05 to 0.85] p = 0.029). Clinical cure was observed in 92% of patients.
CONCLUSION: In this study of treating cUTIs with ertapenem, we have demonstrated good clinical outcomes. A lower than expected microbiological cure rate was observed in those with Klebsiella pneumoniae infection.
Trad ,M.A., Zhong, L.H., Llorin, R.M., Tan, S.Y., Chan, M., Archuleta, S., Sulaiman, Z., Tam, V.H., Lye, D.C. and Fisher, D.A. (2016) Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. Journal of Chemotherapy. May 30th. [Epub ahead of print].
Thank you to our partners for supporting IVTEAM